Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Summit Therapeutics plc (NASDAQ: SMMT).

Full DD Report for SMMT

You must become a subscriber to view this report.


Recent News from (NASDAQ: SMMT)

Proposed Subscription to Raise $25m and Notice of General Meeting
THIS ANNOUNCEMENT (INCLUDING THE APPENDICES) AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, OR INTO ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL...
Source: GlobeNewswire
Date: December, 16 2018 21:05
Summit Therapeutics Announces Departure of Chief Financial Officer
Summit Therapeutics plc  (‘Summit’ or the ’Company’) Summit Therapeutics Announces Departure of Chief Financial Officer Oxford, UK, and Cambridge, MA, US, 17 December 2018 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mech...
Source: GlobeNewswire
Date: December, 16 2018 21:00
Summit Therapeutics to Participate in Jefferies 2018 London Healthcare Conference
Summit Therapeutics plc  (‘Summit’ or the ’Company’) Summit Therapeutics to Participate in Jefferies 2018 London Healthcare Conference Oxford, UK, and Cambridge, MA, US, 7 November 2018 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a...
Source: GlobeNewswire
Date: November, 07 2018 02:00
Summit Recognises C. difficile Awareness Month
Summit Therapeutics plc  (‘Summit’ or the ’Company’) Summit Recognises C. difficile Awareness Month Oxford, UK, and Cambridge, MA, US, 1 November 2018 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiot...
Source: GlobeNewswire
Date: November, 01 2018 03:00
New Research Coverage Highlights Esperion Therapeutics, Summit Therapeutics, Ocwen Financial, Keane Group, Cellectis S.A, and Rapid7 - Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, Oct. 17, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Esperion Therapeutics, Inc. (NASDAQ:ESPR), Summit Therapeutics PLC (NASDA...
Source: GlobeNewswire
Date: October, 17 2018 08:10
Summit Therapeutics to Participate in Upcoming Investor Events
Summit Therapeutics plc  (‘Summit’ or the ’Company’) Summit Therapeutics to Participate in Upcoming Investor Events Oxford, UK, and Cambridge, MA, US, 10 October 2018 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces that manage...
Source: GlobeNewswire
Date: October, 10 2018 03:00
Surrender of Share Options
Summit Therapeutics plc  (‘Summit’ or the ’Company’) Surrender of Share Options Oxford, UK, and Cambridge, MA, US, 8 October 2018 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, announce...
Source: GlobeNewswire
Date: October, 07 2018 22:00
Antibiotic developers in the green on Paratek news
Stoked by the FDA nod for Paratek Pharmaceuticals' ( PRTK +7.4% ) NUZYRA (omadacycline), investors are spreading the love to certain other antibiotic makers. More news on: Paratek Pharmaceuticals, Inc., Achaogen, Tetraphase Pharmaceuticals, Healthcare stocks news, Stocks on the move, ...
Source: SeekingAlpha
Date: October, 03 2018 12:33
Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2018
WASHINGTON , Oct. 3, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations, announced today that 16 of its member companies will present data from their clinical a...
Source: PR Newswire
Date: October, 03 2018 09:14
Summit Highlights Phase 3-Ready Precision Antibiotic Ridinilazole at IDWeek 2018
Summit Therapeutics plc  (‘Summit’ or the ’Company’) Summit Highlights Phase 3-Ready Precision Antibiotic Ridinilazole at IDWeek 2018 Ridinilazole in Development to Treat C. difficile Infection and Reduce Recurrent Disease Oxford, UK, and Camb...
Source: GlobeNewswire
Date: October, 03 2018 07:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-082.202.202.252.1680,552
2018-05-1713.5314.0714.1013.5337,526
2017-02-0311.2510.9511.2510.62510,824
2017-02-0211.4311.2411.7710.47519,357
2017-02-0111.2711.9311.9811.2752,978

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-182006,0813.2889Cover
2018-12-1710,60126,70039.7041Short
2018-12-141004,5822.1825Cover
2018-12-133831,72222.2416Cover
2018-12-125,03712,16441.4091Short

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on SMMT.


About Summit Therapeutics plc (NASDAQ: SMMT)

Logo for Summit Therapeutics plc (NASDAQ: SMMT)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: SMMT)

      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 15 2018
      Registration statement for certain foreign private issuers offered for certain transactions
      Filing Type: F-3Filing Source: edgar
      Filing Date: May, 15 2018
      Filing Type: CT ORDERFiling Source: edgar
      Filing Date: May, 09 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 03 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: April, 24 2018
      Annual and transition report of foreign private issuers under sections 13 or 15(d)
      Filing Type: 20-FFiling Source: edgar
      Filing Date: April, 13 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: April, 11 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: March, 27 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: February, 26 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 14 2018

       

       


      Daily Technical Chart for (NASDAQ: SMMT)

      Daily Technical Chart for (NASDAQ: SMMT)


      Stay tuned for daily updates and more on (NASDAQ: SMMT)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: SMMT)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in SMMT is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of SMMT and does not buy, sell, or trade any shares of SMMT. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/